Attendee search 

Cancer Immunotherapy development

haitong

Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

To continue our development, part of our strategies requires us to constantly seeking high-quality novel drug research and development programs that are open to collaboration opportunities. Relying on strong industry resources and connections built up throughout the years, we welcome partnerships in the following structures: equity investment, intermediary service and project incubation.

iosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.

VC investment focus on healthy care

Our goal is to advance the development of analytical technologies by combining our specialist knowledge from chemistry, biology, physics and computer science and the transfer of our results to science, business and the public are our main goals.

1994年成立上海市国资委直属投资公司

MID Labs has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, we have been instrumental in revolutionizing the ophthalmic field through our products.

MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.

Late stage venture family office

L.E.K. Consulting is a global strategy consulting firm that specializes in corporate strategy, transaction services, and performance improvement. Founded in 1983, we now have more than 1,500 professionals located across major economies worldwide. Clients include Fortune 500, FTSE 100, Eurotop 300, and many of the largest firms in Asia-Pacific.

 

With a reputation for solving the most complex issues, L.E.K. collaborates closely with business leaders and their teams to accelerate the pace and precision of strategic decision-making. L.E.K. works across numerous industry sectors including a strong focus on the healthcare sector.

 

As a leading strategic advisor to the life sciences industry, L.E.K.’s clients include the largest and most advanced pharmaceutical, biotech, medical devices, tools and diagnostics companies. L.E.K.’s global team of life sciences professionals has expertise across all major industry segments and therapeutic areas, and we provide support at each stage of the product life cycle, from drug discovery to commercial optimisation.

 

L.E.K. hosts the Asia Pacific Life Sciences Centre of Excellence in partnership with the Singapore Economic Development Board (“EDB”). This Centre of Excellence (“CoE”) drives thought leadership and innovation to elevate the life sciences ecosystem both in Singapore and across the region.